Tranzyme’s TZP-101 Proof-of-Concept Study Bodes Well For Deal, CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Compound’s promising Phase IIb results should pave the way to an exit for the North Carolina biotech.